Articles On Imugene (ASX:IMU)
Title | Source | Codes | Date |
---|---|---|---|
Why Chalice Mining, Chrysos, GQG, and Westpac shares are falling today
The S&P/ASX 200 Index (ASX: XJO) is under pressure ahead of the Reserve Bank's meeting. In afternoon trade, the benchmark index is down 0.4% to 6,967.3 points. Four ASX shares that are falling more than most today are listed below. H... |
Motley Fool | IMU | 5 months ago |
5 things to watch on the ASX 200 on Tuesday
On Monday, the S&P/ASX 200 Index (ASX: XJO) started the week with a small gain. The benchmark index rose 0.3% to 6,997.4points. Will the market be able to build on this on Tuesday? Here are five things to watch: ASX 200 expected to f... |
Motley Fool | IMU | 5 months ago |
Warren Buffett's cash holdings just hit a record $241 billion. Here's why
Warren Buffett is called the Oracle of Omaha for good reason. Atop his phenomenal investing success, the 93-year-old CEO of Berkshire Hathaway (NYSE: BRK.A) is well known for sharing his market acumen with eager disciples across the world.... |
Motley Fool | IMU | 5 months ago |
Everything you need to know about the Westpac dividend
Owners of Westpac Banking Corp (ASX: WBC) shares will soon be getting their FY23 final dividend payment after the bank released its FY23 report. It was a successful period for the ASX bank share â the business reported a 26% increase in... |
Motley Fool | IMU | 5 months ago |
Why Imugene, Mayne Pharma, Westpac, and Wildcat shares are storming higher
The S&P/ASX 200 Index (ASX: XJO) has started the week positively. In afternoon trade, the benchmark index is up 0.3% to 6,998.1 points. Four ASX shares that are rising more than most today are listed below. Here's why they are stormi... |
Motley Fool | IMU | 5 months ago |
Imugene (ASX: IMU) reports positive early signals in Phase 1 VAXINIA study, shares jump
Highlights To date, 34 heavily treated patients administered with CF33-hNIS All treatments have been ascertained tolerable and safe Trial expansion is planned for ten patients with bile duct cancer Shares of Imugene Limited (ASX:... |
Kalkine Media | IMU | 5 months ago |
Hope grows with positive signals in Imugene cancer trial
Imugene has recorded positive early signals from the first phase of its metastatic advanced solid tumour clinical trial evaluating the safety and efficacy of its novel cancer-killing virus known as “Vaxinia”. |
The West | IMU | 5 months ago |
Imugene reports positive early signals from Phase 1 trial of CF33-hNIS cancer killer
A Phase 1 metastatic advanced solid tumours (MAST) trial evaluating the safety and efficacy of novel cancer-killing virus CF33-hNIS (VAXINIA) has delivered positive early signals for immuno-oncology company Imugene (ASX: IMU). The study str... |
smallcapsau.mystagingwebsite.com | IMU | 5 months ago |
The Imugene share price just leapt 10%. Here's why the ASX biotech stock is rocketing
The Imugene Ltd (ASX: IMU) share price is soaring higher today. Shares in the ASX biotechnology company closed on Friday trading for 4.8 cents. At the time of writing, shares are changing hands for 5.3 cents apiece, up 10.4%. For some con... |
Motley Fool | IMU | 5 months ago |
ASX Health Stocks: PYC on the same page with FDA, Cleo’s cancer test peer-reviewed
PYC to take ADOA drug to human clinical trials Imugene provides update of its Phase 1 MAST (Metastatic Advanced Solid Tumours) trial Cleo’s CleoDX Triage Test was published in ‘Cancer’ journal PYC to commence human trials in 2024 after... |
Stockhead | IMU | 5 months ago |
Whispir share price rockets 60% with ASX tech share in takeover crosshairs
The Whispir Ltd (ASX: WSP) share price is shooting the lights out on Monday. The ASX tech share closed on Friday trading for 30 cents. At the time of writing, shares are swapping hands for 48 cents apiece, up a whopping 60%. Here's why inv... |
Motley Fool | IMU | 5 months ago |
Imugene enters final stages of cancer tumour trials
Imugene has taken a further leap forward in its mission to track down and kill cancer tumours by advancing to the final cohort stages for both of the intravenous dose escalation trials of its “Vaxinia” virus. |
The West | IMU | 5 months ago |
Imugene enters final stages of cancer tumour trials
Imugene has taken a further leap forward in its mission to track down and kill cancer tumours by advancing to the final cohort stages for both of the intravenous dose escalation trials of its “Vaxinia” virus. |
The West | IMU | 5 months ago |
Imugene (ASX: IMU) advances to final cohorts under Phase 1 MAST trial
Highlights Phase 1 MAST trial has cleared cohort 4 of the IV arm of the monotherapy and IV cohort 2 of combination study. The study is evaluating the safety of VAXINIA, novel cancer-killing virus CF33-hNIS. Next cohort is open in IV a... |
Kalkine Media | IMU | 5 months ago |
Imugene reaches next cohorts in monotherapy and combination study for cancer-killing virus, Vaxinia
Imugene (ASX:IMU) reaches the next cohort in the IV arm of its monotherapy dose escalation study, and also its combination study for the cancer-killing virus, Vaxinia As a result, cohort five of the IV arm for the monotherapy dose escala... |
themarketherald.com.au | IMU | 5 months ago |
Imugene says next cohort reached in intravenous arms of monotherapy and combination study
Clinical-stage immuno-oncology company Imugene (ASX: IMU) has announced that its Phase 1 MAST (metastatic advanced solid tumours) trial evaluating the safety of novel cancer-killing virus CF33hNIS (VAXINIA) has cleared cohort 4 of t... |
BiotechDispatch | IMU | 5 months ago |
Imugene kicks off world-first cancer drug trial
ASX-listed medtech Imugene has dosed the first patient with its novel immunotherapy drug candidate “onCARlytics” which has the potential to target and eradicate solid tumours. |
The West | IMU | 5 months ago |
ASX Health Stocks: Althea’s cannabis oil approved for reimbursement in Ireland, Imugene begins Phase 1 trial
Althea’s cannabis oil approved for reimbursement in Ireland Imugene dosed first patient in onCARlytics Phase 1 trial on solid tumours Althea’s cannabis oil approved for reimbursement Cannabis company Althea Group (ASX:AGH) has announced... |
Stockhead | IMU | 5 months ago |
Imugene announces phase 1 clinical trial opens with onCARlytics CD19 virus technology
Imugene (ASX:IMU) has announced that its CD19 oncolytic virotherapy drug candidate, onCARlytics, has commenced a Phase 1 clinical trial, with the first patient now dosed. |
BiotechDispatch | IMU | 5 months ago |
Imugene trials take centre stage at global cancer congress
Imugene is poised to secure further development opportunities for its “super-charged” cell immunotherapy programs after putting them on show at what it says is the world’s most influential oncology platform. |
The West | IMU | 5 months ago |
Imugene showcases B cell and OV platforms at ESMO Congress
Imugene (ASX:IMU) announces that its B cell immunotherapy, HER-Vaxx, and CF33 oncolytic virotherapy CHECKVacc are being showcased at the ESMO Congress this week in Madrid IMU is a clinical-stage immuno-oncology company, that aims to cont... |
themarketherald.com.au | IMU | 5 months ago |
Check Up: Why Goldman Sachs won’t change its ratings on 3 ASX stocks despite Ozempic-driven selloff
News relating to Novo Nordisk’s Ozempic has led to a selloff in some ASX stocks CSL, FPH, and RMD fell heavily last week But Goldman analysts say they won’t change ratings on these 3 stocks Goldman Sachs analysts said they will make no... |
Stockhead | IMU | 6 months ago |
FDA clears licence pathway for Imugene cancer trials
The US FDA has stamped Imugene as the exclusive sponsor for its allogeneic “azer-cel” cancer treatment after transferring an investigational new drug application to the company from Precision Biosciences. |
The West | IMU | 6 months ago |
US FDA transfers azer-cel IND application to Imugene
The US Food and Drug Administration (FDA) has transferred an investigational new drug (IND) application for allogeneic CD19 CAR T azer-cel from Precision Biosciences Inc to Imugene (ASX: IMU). The transfer follows Imugene’s acquisition of a... |
smallcaps.wpenginepowered.com | IMU | 6 months ago |
The Overnight Report: Bottom Identified?
World Overnight SPI Overnight 7055.00 – 13.00 – 0.18% S&P ASX 200 7030.30 – 7.90 – 0.11% S&P500 4274.51 + 0.98 0.02% Nasdaq Comp 13092.85 + 29.24 0.22% DJIA 33550.27 – 68.61 – 0.20% S&P500 VIX 18.22 – 0.72 – 3.80%... |
FNArena | IMU | 6 months ago |
Check Up: How supramolecular technology is used in biotech, and why L’Oréal wants to get its hands on it
L’Oréal to take minority stake in Chinese startup Shinehigh Innovation Shinehigh is developing supramolecular technology which could be used in the fashion industry Best and worst performing ASX biotechs over the past couple of weeks Be... |
Stockhead | IMU | 6 months ago |
Why Bannerman, Clover, Polynovo, and Pro Medicus shares are pushing higher
The S&P/ASX 200 Index (ASX: XJO) is out of form on Tuesday. In afternoon trade, the benchmark index is down 0.5% to 7,043.1 points. Four ASX shares that are not letting that hold them back are listed below. Here's why they are pushing... |
Motley Fool | IMU | 6 months ago |
This ASX ETF just hit an all-time high. Too late to buy?
It hasn't been a great day for the S&P/ASX 200 Index (ASX: XJO) and most ASX shares so far this Tuesday. At the time of writing, the ASX 200 has slipped by 0.71%. But that hasn't stopped one ASX exchange-traded fund (ETF) from hitting... |
Motley Fool | IMU | 6 months ago |
Why are ASX uranium shares so hot right now?
Another day, another set of 52-week highs for ASX uranium shares! Most uranium miners are rising on Tuesday, in contrast to the rest of the market. The S&P/ASX 200 Energy Index (ASX: XEJ) started the day higher but is now down 0.19%... |
Motley Fool | IMU | 6 months ago |
5 ASX 300 shares smashing new 52-week highs on Tuesday
It's been a pretty awful start to this Tuesday's trading for the S&P/ASX 300 Index (ASX: XKO) and ASX 300 shares so far today. At present, the ASX 300 has slipped by 0.32% and is back to around 7,000 points. So given this slip for the... |
Motley Fool | IMU | 6 months ago |
Here are the top 10 ASX 200 shares today
The S&P/ASX 200 Index (ASX: XJO) has delighted investors hoping for a reprieve from the share market today with a green session. After falling every single trading day last week, the ASX... |
Motley Fool | IMU | 6 months ago |
Why Boss Energy, Imugene, Polynovo, and TechnologyOne shares are racing higher
The S&P/ASX 200 Index (ASX: XJO) is out of form on Monday. In afternoon trade, the benchmark index is down 0.2% to 7,057 points. Four ASX shares that are not letting that hold them back are listed below. Here's why they are rising:... |
Motley Fool | IMU | 6 months ago |
Imugene stacks up $53.2m for cancer-fighting mission
Cancer fighter Imugene has positioned itself as one of the most cashed-up med-techs on the ASX after raising a further $18.2 million from a share placement plan (SPP) to add to a previous $35 million placement. |
The West | IMU | 6 months ago |
Why Bell Potter just upgraded this ASX 200 tech share to buy
The TechnologyOne Ltd (ASX: TNE) share price is starting the week strongly. At the time of writing, the ASX 200 tech share is up 2.5% to $15.65. This compares favourably to the performance of the ASX 200 index, which is down 0.35%. Why is... |
Motley Fool | IMU | 6 months ago |
Imugene raises $18.2m to fund azer-cel worldwide licencing deal
Clinical stage immuno-oncology company Imugene (ASX: IMU) has raised $18.2 million from a share purchase plan component of a capital raising exercise to fund the acquisition of worldwide licensing rights for lead candidate azer-cel to targe... |
smallcaps.wpenginepowered.com | IMU | 6 months ago |
The Overnight Report: Over To You Jerome
World Overnight SPI Overnight 7186.00 – 14.00 – 0.19% S&P ASX 200 7196.60 – 33.80 – 0.47% S&P500 4443.95 – 9.58 – 0.22% Nasdaq Comp 13678.19 – 32.05 – 0.23% DJIA 34517.73 – 106.57 – 0.31% S&P500 VIX 14.11 + 0.11 0.... |
FNArena | IMU | 6 months ago |
ASX cancer stocks guide: Here’s everything you need to know
According to the World Health Organisation (WHO), cancer is the leading cause of death globally. WHO defines cancer as a generic term for a large group of diseases that can affect any part of the body with malignant tumours and neoplasms. W... |
Stockhead | IMU | 7 months ago |
CLOSING BELL: Local markets dragged lower by central bank angst; lithium minnows and New Hope offer some hope
The ASX 200 benchmark falls 0.5% as central bank boogeymen spook investors Energy pretty much on its own out front of the rest of the sectors Small caps led by lithium and new metal minnows with some sturdy new finds Local markets hav... |
Stockhead | IMU | 7 months ago |
Check Up: What is the FDA emergency use authorisation, and which ASX stocks were given approval?
The FDA has just approved an emergency use authorisation for new Covid-19 vaccines What is emergency use authorisation, and which ASX stocks have got it? We look at the best and worst performing ASX biotechs over the couple of weeks On... |
Stockhead | IMU | 7 months ago |
Here are the top 10 ASX 200 shares today
The S&P/ASX 200 Index (ASX: XJO) had another shaky day on Tuesday. Yesterday seemed to show that investors couldn't decide what they wanted out of the markets, with stints on both positive and ne... |
Motley Fool | IMU | 7 months ago |
Imugene secures Japan patent for lung cancer vaccine
Clinical-stage immuno-oncology company Imugene has secured new Japan Patent Office protection for its “PD1-Vaxx” that is currently in the development stage of a bid to target non-small cell lung cancer. |
The West | IMU | 7 months ago |
Imugene granted Japanese patent for PD1-Vaxx to treat non-small cell lung cancer
Clinical stage immuno-oncology company Imugene (ASX: IMU) has been granted a new patent by the Japanese Patent Office for its PD1-Vaxx clinical candidate. The grant protects the immunotherapeutic drug, which is a first-in-class programmed d... |
smallcaps.wpenginepowered.com | IMU | 7 months ago |
Imugene’s (ASX: IMU) PD1-Vaxx receives key Japanese patent
Highlights Imugene’s first-in-class programmed death-1 (PD1) vaccine, PD1-Vaxx has been granted a Japanese patent. The patent extends protection to the matter composition and treatment method in cancer. Imugene Limited (ASX: IMU) h... |
Kalkine Media | IMU | 7 months ago |
Beaten-up ASX 200 evictee Imugene stock surges on patent news
Imugene Limited (ASX: IMU) stock is in great demand with investors on Tuesday. In morning trade, the beaten-down biotech share is up almost 7% to 6.3 cents. Why is Imugene stock rising? Investors have been buying the biotech's shares after... |
Motley Fool | IMU | 7 months ago |
Imugene secures new patent in Japan for PD1-Vaxx clinical drug candidate
Clinical-stage immuno-oncology company Imugene (ASX:IMU) has announced the grant of a new patent for its PD1-Vaxx clinical drug candidate. |
BiotechDispatch | IMU | 7 months ago |
ASX Today: Stocks to watch on Tuesday
Futures point to the ASX opening modestly higher, bolstered by gains on Wall Street overnight. Overnight, Tesla shares surged 10 per cent in a vote of confidence for artificial intelligence, boosting the Nasdaq. Back home, here are so... |
themarketherald.com.au | IMU | 7 months ago |
FDA throws support behind Imugene cancer drug trial
Cancer-fighter Imugene has received positive feedback from the US Food and Drug Administration on its proposed trials and commercial manufacture of “Azer-cel” to treat patients with certain blood cancers. |
The West | IMU | 7 months ago |
Imugene gets FDA thumbs-up on anti-cancer drug manufacture
Cancer-fighter Imugene has received positive feedback from the US Food and Drug Administration on its proposed trials and commercial manufacture of “Azer-cel” to treat patients with certain blood cancers. |
The West | IMU | 7 months ago |
ASX Health Stocks: Lumos granted US FDA emergency-use approval for virus test kit, ViraDx
Lumos granted approvals by the US FDA for the ViraDx test Imugene receives positive feedback from FDA for CAR T cell therapy Genetic Technology expands its geneType Multi-Risk Test in Australia Lumos granted US FDA approval for ViraDx M... |
Stockhead | IMU | 7 months ago |
Imugene moves forward with improved manufacturing process for azer-cel
Imugene (ASX: IMU) has announced positive feedback from the US Food and Drug Administration (FDA) on a manufacturing process for lead candidate azer-cel (azercabtagene zapreleucel or allogeneic CD19 CAR T) for the treatment of patients with... |
smallcaps.wpenginepowered.com | IMU | 7 months ago |